LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Suletud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	6.8M -8.1M
Müük	33M 72M
Kasumimarginaal	-11.242
Töötajad	105
EBITDA	6.7M -5.4M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	19. märts 2026

Turustatistika
By TradingEconomics
Turukapital	96M 187M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. märts 2026, 18:43 UTC

Uudisväärsed sündmused

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3. märts 2026, 17:33 UTC

Omandamised, ülevõtmised, äriostud

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3. märts 2026, 23:45 UTC

Market Talk

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3. märts 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3. märts 2026, 23:25 UTC

Market Talk

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3. märts 2026, 23:25 UTC

Market Talk

Global Energy Roundup: Market Talk

3. märts 2026, 22:38 UTC

Uudisväärsed sündmused

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3. märts 2026, 22:16 UTC

Tulu

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3. märts 2026, 22:09 UTC

Tulu

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3. märts 2026, 22:06 UTC

Tulu

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3. märts 2026, 22:05 UTC

Tulu

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3. märts 2026, 22:03 UTC

Tulu

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Tech, Media & Telecom Roundup: Market Talk

3. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

3. märts 2026, 21:45 UTC

Uudisväärsed sündmused

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3. märts 2026, 21:37 UTC

Tulu

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3. märts 2026, 21:26 UTC

Uudisväärsed sündmused

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3. märts 2026, 20:31 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3. märts 2026, 20:04 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3. märts 2026, 19:17 UTC

Market Talk

Uudisväärsed sündmused

Gold and Silver Drop as Energy Surges -- Market Talk

3. märts 2026, 18:43 UTC

Tulu

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3. märts 2026, 18:29 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

3. märts 2026, 18:29 UTC

Market Talk

Uudisväärsed sündmused

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3. märts 2026, 18:22 UTC

Uudisväärsed sündmused

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3. märts 2026, 18:22 UTC

Uudisväärsed sündmused

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3. märts 2026, 18:17 UTC

Market Talk

Uudisväärsed sündmused

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3. märts 2026, 18:14 UTC

Tulu

How Long Can Anthropic Play Defense? -- WSJ

3. märts 2026, 17:41 UTC

Uudisväärsed sündmused

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3. märts 2026, 17:36 UTC

Uudisväärsed sündmused

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3. märts 2026, 17:28 UTC

Omandamised, ülevõtmised, äriostud

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.